Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05396859
Title Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute

acute myeloid leukemia


Decitabine and Cedazuridine + Entrectinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST